AntalGenics
Private Company
Funding information not available
Overview
AntalGenics is a private, preclinical-stage biotech founded in 2015 and based in Elche, Spain, with a focus on neurobiology-driven therapies for pain, pruritus, and dermatological conditions. The company has secured substantial non-dilutive grant funding from Spanish and EU sources and completed an investment round with Capital Cell. Its pipeline includes programs for psoriatic pruritus and arthritic pain, alongside a portfolio of licensed cosmeceutical ingredients, positioning it with a hybrid model of therapeutic development and service-based R&D collaborations.
Technology Platform
Sensory neurobiology platform focused on peripheral mechanisms and topical treatments for the discovery of novel analgesic, anti-pruritic, and dermocosmetic active molecules. Utilizes in silico processes for identification and development.
Opportunities
Risk Factors
Competitive Landscape
AntalGenics competes with numerous biopharma companies developing systemic and topical therapies for pain and pruritus, including large caps and specialized biotechs. In dermocosmetics, it competes with global specialty chemical firms and dedicated active ingredient suppliers, differentiating itself through a neurobiology-focused approach.